Loading
Antiviral Therapy · Journal article
Virulence · August 2, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review examining the putative role of lactylation in influenza A virus infection, explicitly framed as a hypothesis-generating synthesis because direct evidence in IAV is limited. The authors propose that lactylation of viral ribonucleoprotein components, regulation of host SIRT1, and modulation of innate immune pathways may be mechanistically important, while noting that these mechanisms remain largely untested in the IAV context.
Journal article. Influenza A virus infection in humans and animals; macrophages and immune cells as model systems.
IAV stabilizes HIF-1α and elevates HK2 and LDHA expression, leading to markedly increased lactate levels Components of the IAV ribonucleoprotein (vRNP) complex undergo lactylation during infection, potentially facilitating vRNP-mediated transcription and replication Host deacetylase SIRT1 suppresses IAV replication by removing lactyl groups from viral components, and IAV counteracts this defense by downregulating SIRT1 expression
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies lactylation as a potential novel therapeutic target for antiviral drug development, but clinicians and researchers should recognize that the evidence is primarily mechanistic and hypothesis-based, derived largely from other viral systems rather than definitive IAV studies. Direct experimental validation in IAV infection models is required before translation to clinical practice.
This is a forward-looking review that synthesizes established lactylation mechanisms from other viral systems and proposes testable hypotheses for IAV, explicitly acknowledging that direct research on lactylation in IAV infection is still in early stages with limited primary studies available.
This review identifies lactylation as a potential novel therapeutic target for antiviral drug development, but clinicians and researchers should recognize that the evidence is primarily mechanistic and hypothesis-based, derived largely from other viral systems rather than definitive IAV studies. Direct experimental validation in IAV infection models is required before translation to clinical practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Influenza A virus (IAV) is a major respiratory pathogen causing seasonal epidemics and pandemics, posing serious threats to public health and livestock. The high mutation rate of IAV leads to vaccine mismatches and drug-resistant variants, underscoring the need for novel antiviral strategies. This review examines the role of lactylation in IAV-host interactions, focusing on three core questions: how IAV induces lactylation, how lactylation reshapes antiviral immunity, and how IAV exploits lactylation for immune evasion. Key findings include lactylation of viral vRNP components required for efficient replication and the host deacetylase SIRT1, which suppresses IAV replication by removing these lactyl groups. IAV counteracts this defense by downregulating SIRT1 expression. Lactylation also regulates cGAS-STING, RLR-MAVS, and IFN signaling pathways. The therapeutic potential of targeting lactate metabolism and SIRT1 is discussed. Understanding lactylation in IAV infection may open new avenues for antiviral drug development.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.